Biochemical and Pharmaceutical Technology Department, University of São Paulo, São Paulo, Brazil.
Food Biosciences Department, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.
Gut Microbes. 2022 Jan-Dec;14(1):2004071. doi: 10.1080/19490976.2021.2004071.
Pediocin PA-1 is a class IIa bacteriocin that is particularly effective against the foodborne pathogen . The loss of activity of PA-1 pediocin due to methionine oxidation is one of the challenges that limit the wider application of the bacteriocin. In this study, we heterologously expressed an oxidation resistant form of pediocin PA-1, i.e., pediocin M31L, and compared its activity to that of native pediocin PA-1 and to penocin A, a pediocin-like bacteriocin that displays a narrower antimicrobial spectrum. Minimal inhibitory concentration assays revealed that pediocin M31L was as effective as PA-1 and more effective than synthetic penocin A against with negligible activity against a range of obligate anaerobic commensal gut bacterial species. The anti- activity of these pediocins was also assessed in a simulated human distal colon model assay using the , spiked at 6.5 0.13 Log CFU/mL, as a bioindicator. At 24 h, pediocin M31L and penocin A (2.6 μM) reduced counts to 3.5 0.4 and 3.64 0.62 Log CFU/mL, respectively, whereas counts were considerably higher, i.e. 7.75 0.43 Log CFU/mL, in the non-bacteriocin-containing control. Ultimately, it was established that synthetic penocin A and the stable pediocin M31L derivative, heterologously produced, display effective anti- activity in a human gut environment.
短小菌素 PA-1 是一种 IIa 型细菌素,对食源性病原体具有特别的抑制效果。由于蛋氨酸氧化导致短小菌素 PA-1 丧失活性是限制该细菌素更广泛应用的挑战之一。在本研究中,我们异源表达了一种氧化抗性短小菌素 PA-1 形式,即短小菌素 M31L,并将其活性与天然短小菌素 PA-1 和具有较窄抗菌谱的类似短小菌素的抑菌素 penocin A 进行了比较。最小抑菌浓度分析显示,短小菌素 M31L 与 PA-1 一样有效,对 比合成的 penocin A 更有效,对一系列严格厌氧菌共生肠道细菌的活性可忽略不计。这些抑菌素在使用 (浓度为 6.5 0.13 Log CFU/mL)作为生物指示剂的模拟人远端结肠模型试验中,其抗 活性也得到了评估。在 24 小时时,短小菌素 M31L 和 penocin A(2.6 μM)分别将 计数降低到 3.5 0.4 和 3.64 0.62 Log CFU/mL,而在不含抑菌素的对照中, 计数则明显更高,即 7.75 0.43 Log CFU/mL。最终,研究结果表明,合成的 penocin A 和稳定的异源生产的短小菌素 M31L 衍生物在人类肠道环境中具有有效的抗 活性。